InSilico Medicine nominates AI-designed VAV1 degrader ISM9546 for autoimmune disease
What's the deal? On 13 October 2026 InSilico Medicine nominated ISM9546, an AI-designed, orally administered 'molecular glue degrader' aimed at the protein VAV1, as a preclinical candidate for autoimmune diseases including inflammatory bowel disease (IBD) and rheumatoid arthritis.
How it works: Molecular glue degraders are small molecules that hijack the cell's protein-recycling machinery to destroy a specific disease-driving protein. Here the target is VAV1, a protein that helps activate immune cells; it was long considered 'undruggable' because it lacks a conventional drug-binding pocket. ISM9546 was designed with InSilico's Pharma.AI generative chemistry platform and is deliberately 'peripherally restricted' — kept out of the brain to reduce central-nervous-system risks.
Why it matters: In preclinical studies the compound showed sub-nanomolar potency at degrading VAV1, reduced disease activity in animal models of colitis within days, and cut inflammatory pathology scores by roughly 60%. ISM9546 is InSilico's 35th preclinical candidate nominated since 2021 and its 11th in the first ten months of 2026, underscoring the pace of the company's AI-driven discovery engine as it moves beyond conventional small molecules into newer therapeutic modes.
Read more: InSilico Medicine, 13 October 2026 · BioWorld, 14 October 2026